Highest-materiality recent filing
Arbutus shareholders approve 2026 omnibus equity plan authorizing 16.3M shares
Shareholders elected all five director nominees: Androski, Beardsley, Bishop, Gline, Sawhney.
Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement
Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.
Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B
FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.
Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures
Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.
Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026
Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.
Arbutus wins partial summary judgment in Moderna patent case; enablement goes to trial
Court bars Moderna's obviousness defense: IPR estoppel applies to '435 Patent, issue preclusion bars routine-optimization and phospholipid-range arguments.
Arbutus patent case vs Moderna to proceed in Delaware; Section 1498 defense limited
Court denies Moderna's summary judgment on Section 1498 for most vaccine doses; only government employee doses go to Court of Federal Claims.
EPO revokes Arbutus' European patent EP 2279254; company plans appeal
EPO Board of Appeal revoked Arbutus' European patent EP 2279254 on Jan 15, 2026; verbal decision without reasons; written decision expected in months.
Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling
Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.
Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive
Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.
Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction
Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.
Court adopted Arbutus's proposed construction for 'fully encapsulated' as 'contained inside' in five LNP patents.
Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board
Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.
Arbutus reacquires Greater China rights to imdusiran from Qilu Pharma; launches HBV SAB
Mutual termination of License Agreement with Qilu Pharmaceutical for imdusiran in Greater China; no payments and all rights revert to Arbutus.
Arbutus shareholders elect all five director nominees, approve say-on-pay and auditor at 2025 AGM
All five director nominees elected: Androski, Beardsley, Bishop, Gline, Hasija (avg 123M votes for).
Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients
Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.
Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025
In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.
Five abstracts accepted for poster presentation at EASL Congress 2025 (May 7-10, Amsterdam); one late-breaker (LB25153).
Arbutus Biopharma finalizes separation agreements with ex-CMO and ex-CFO; updates Moderna trial date
CMO Karen Sims terminated without cause effective March 25, 2025; enters 30-day consulting agreement with hourly fee and extended option exercise to March 24, 2026.
Arbutus reports FY2024 net loss $69.9M; cuts workforce 57%, appoints new CFO
Net loss for 2024 was $69.9M ($0.38/share) vs $72.8M ($0.44) in 2023; revenue $6.2M down from $18.1M.
Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.
Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign
All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.
Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M
Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.
Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a
Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).
Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026
Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.
Arbutus to present imdusiran Phase 2a data in 4 posters at AASLD, including 2 late-breakers
Four poster presentations at AASLD 2024 (Nov 15-19, San Diego) feature imdusiran, an RNAi therapeutic for chronic HBV.
CSO Michael J. Sofia to retire Dec 31, 2024; amendment clarifies severance and non-compete
CSO Michael J. Sofia will retire effective December 31, 2024; amendment to employment agreement dated Oct 11, 2024.
Arbutus and Moderna agree to extend patent trial schedule to Sept 2025
Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.
Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026
Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.
Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV
Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.
Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks
33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.
Arbutus shareholders approve 9.5M share increase under 2016 Omnibus Plan
Amendment increases aggregate authorized shares by 9,500,000 common shares.
Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss
Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).
Arbutus CSO Michael Sofia to retire Dec 31, 2024; no successor named yet.
Dr. Michael Sofia, co-founder and Chief Scientific Officer, notified retirement effective December 31, 2024.
Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026
Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.
Arbutus Biopharma Announces Claim Construction Ruling in Patent Lawsuit Against Moderna
Court agreed with Arbutus and Genevant that the claimed mol. % ranges for total lipid ('069 patent) are not limited to 'finished' particles and include standard variation.
Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026
Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.
Cash, equivalents and investments ~$132M at Dec 31, 2023; net burn expected $63-67M in 2024 vs ~$85M in 2023.
CEO Collier retires, gets $207K bonus; interim CEO McElhaugh gets $515K salary + $127.5K stipend
William Collier retired as CEO effective Dec 31, 2023; receives prorated 50% target bonus of $207,058.
Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.
Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO
William H. Collier retires as President, CEO, and director effective Dec 31, 2023.
Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire
Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.
Arbutus announces multiple abstracts accepted for AASLD 2023, including late-breaking imdusiran data
Late-breaking poster on imdusiran (AB-729) followed by VTP-300 or placebo in chronic hepatitis B subjects.
Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.
Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1
Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).
Arbutus appoints Melissa V. Rewolinski, PhD to its board of directors
Melissa V. Rewolinski appointed to board effective July 12, 2023; board expands to seven members.
Arbutus appoints Karen Sims as CMO, Christopher Naftzger as GC and CCO
Dr. Karen Sims promoted from VP Clinical Development to Chief Medical Officer, effective immediately.
Arbutus reports preliminary AB-729 + IFN data at EASL; HBsAg declines seen
Mean HBsAg decline of 1.6 log10 at week 24 during AB-729 lead-in phase.
Arbutus doses first patient in Phase 2a triple combo arm adding nivolumab for chronic HBV
First patient dosed in additional arm of AB-729 Phase 2a trial including nivolumab (Opdivo) with VTP-300.
Arbutus to present AB-729 and AB-836 data at EASL Congress 2023
AB-729 + IFN in virally suppressed chronic HBV: well tolerated, mean HBsAg decline >1.6 log10 after 24 weeks.
the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.
the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.
Daniel Burgess
Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.
James Meyers
Richard C. Henriques
Frank Torti, M.D., chairperson of the Board
Melissa V. Rewolinski, Ph.D.
Keith Manchester, M.D.
appointed Ms. Androski as chairperson of the Board
Michael J. McElhaugh
As previously disclosed, Michael J. Sofia announced his retirement as Chief Scientific Officer of Arbutus Biopharma, Inc. (the “Company”), a subsidiary of Arbutus Biopharma Corporation, effective December 31, 2024.
Max materiality 0.90 · Median 0.65 · Most common event other_material